复发或反应不佳的急性髓系白血病患者的缓解诱导对比立即异基因造血干细胞移植(ASAP):一项随机、开放标签、3期、非劣效性试验
ASAP试验将281例非有利风险、首次诱导后未完全缓解或未经治疗首次复发的急性髓系白血病患者随机分配至缓解诱导组或疾病控制组(立即异基因HSCT)。在意向治疗人群中,疾病控制组治疗成功116/140(83%),缓解诱导组112/141(79%),非劣效性检验p=0.036,但在2.5%显著性水平下未能证明非劣效性。疾病控制组3级及以上非血液学不良事件更少(21% vs 61%),住院时间更短。
要点
- 疾病控制组与缓解诱导组的治疗成功率差异为3.4%(95%CI -5.8至12.6),在2.5%显著性水平下未能证明非劣效性。
- 疾病控制组3级及以上非血液学不良事件发生率为21%(30/140),低于缓解诱导组的61%(86/141)。
- 从随机化到异基因HSCT,疾病控制组中位住院时间较缓解诱导组少27天(15天 vs 42天)。
核心结论
- 在2.5%显著性水平下未能证明疾病控制相对于缓解诱导的非劣效性。
- 缓解诱导组的治疗成功率在统计学上并不优于疾病控制组。
- 对于有干细胞供者且适合的缓解不佳或复发急性髓系白血病患者,观察等待和立即移植可能是一种替代选择。
- 需要更多随机对照的意向移植试验来确定活动性急性髓系白血病患者移植前的最佳治疗。
研究设计与样本
- 随机、开放标签、3期、非劣效性试验,纳入年龄18至75岁、非有利风险、首次诱导后未完全缓解或未经治疗首次复发的急性髓系白血病患者281例。
- 患者按1:1随机分配至缓解诱导组(141例)或疾病控制组(140例),采用可变区组长度的区组随机化,按年龄、急性髓系白血病风险和疾病状态分层。
- 缓解诱导方案为:大剂量阿糖胞苷(3 g/m2静脉注射,>60岁或有严重合并症者1 g/m2静脉注射)每日两次,第1-3天,联合米托蒽醌(10 mg/m2静脉注射)第3-5天;疾病控制组为立即异基因HSCT。
- 主要终点为异基因HSCT后第56天完全缓解(治疗成功),非劣效性界值为5%,单侧1型错误为2.5%,在意向治疗和符合方案人群中分析。
- 试验已完成,注册号ClinicalTrials.gov NCT02461537;2015年9月17日至2022年1月12日入组。
主要发现
- 疾病控制组140例中135例(96%)接受异基因HSCT,其中97例(69%)仅观察等待;缓解诱导组141例中134例(95%)接受挽救化疗,随后128例(91%)接受异基因HSCT。
- 意向治疗人群治疗成功:疾病控制组116/140(83%)vs 缓解诱导组112/141(79%),非劣效性检验p=0.036;符合方案人群:疾病控制组116/138(84%)vs 缓解诱导组109/134(81%),非劣效性检验p=0.047。
- 治疗成功率差异:意向治疗人群疾病控制组较缓解诱导组高3.4%(95%CI -5.8至12.6);符合方案人群高2.7%(95%CI -6.3至11.8)。
- 3级及以上非血液学不良事件:疾病控制组30/140(21%)vs 缓解诱导组86/141(61%),χ2检验p<0.0001。
- 随机化至预处理开始期间,疾病控制组2例死于疾病进展、0例死于治疗相关并发症;缓解诱导组2例死于疾病进展、2例死于治疗相关并发症。
临床怎么用
- 作者认为,对于有干细胞供者且适合的缓解不佳或复发急性髓系白血病患者,观察等待和立即移植可能是一种替代选择。
- 作者建议需要更多随机对照的意向移植试验来确定活动性急性髓系白血病患者移植前的最佳治疗。
局限性
- 在2.5%显著性水平下未能证明疾病控制相对于缓解诱导的非劣效性。
- 缓解诱导组的治疗成功率在统计学上并不优于疾病控制组。
- 需要更多随机对照的意向移植试验来确定活动性急性髓系白血病患者移植前的最佳治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Whether high-dose cytarabine-based salvage chemotherapy, administered to induce complete remission in patients with poor responsive or relapsed acute myeloid leukaemia scheduled for allogeneic haematopoietic stem-cell transplantation (HSCT) after intensive conditioning confers a survival advantage, is unclear. METHODS: To test salvage chemotherapy before allogeneic HSCT, patients aged between 18 and 75 years with non-favourable-risk acute myeloid leukaemia not in complete remission after first induction or untreated first relapse were randomly assigned 1:1 to remission induction with high-dose cytarabine (3 g/m2 intravenously, 1 g/m2 intravenously for patients >60 years or with a substantial comorbidity) twice daily on days 1-3 plus mitoxantrone (10 mg/m2 intravenously) on days 3-5 or immediate allogeneic HSCT for the disease control group. Block randomisation with variable block lengths was used and patients were stratified by age, acute myeloid leukaemia risk, and disease status. The study was open label. The primary endpoint was treatment success, defined as complete remission on day 56 after allogeneic HSCT, with the aim to show non-inferiority for disease control compared with remission induction with a non-inferiority-margin of 5% and one-sided type 1 error of 2·5%. The primary endpoint was analysed in both the intention-to-treat (ITT) population and in the per-protocol population. The trial is completed and was registered at ClinicalTrials.gov, NCT02461537. FINDINGS: 281 patients were enrolled between Sept 17, 2015, and Jan 12, 2022. Of 140 patients randomly assigned to disease control, 135 (96%) proceeded to allogeneic HSCT, 97 (69%) after watchful waiting only. Of 141 patients randomly assigned to remission induction, 134 (95%) received salvage chemotherapy and 128 (91%) patients subsequently proceeded to allogeneic HSCT. In the ITT population, treatment success was observed in 116 (83%) of 140 patients in the disease control group versus 112 (79%) of 141 patients with remission induction (test for non-inferiority, p=0·036). Among per-protocol treated patients, treatment success was observed in 116 (84%) of 138 patients with disease control versus 109 (81%) of 134 patients in the remission induction group (test for non-inferiority, p=0·047). The difference in treatment success between disease control and remission induction was estimated as 3·4% (95% CI -5·8 to 12·6) for the ITT population and 2·7% (-6·3 to 11·8) for the per-protocol population. Fewer patients with disease control compared with remission induction had non-haematological adverse events grade 3 or worse (30 [21%] of 140 patients vs 86 [61%] of 141 patients, χ2 test p<0·0001). Between randomisation and the start of conditioning, with disease control two patients died from progressive acute myeloid leukaemia and zero from treatment-related complications, and with remission induction two patients died from progressive acute myeloid leukaemia and two from treatment-related complications. Between randomisation and allogeneic HSCT, patients with disease control spent a median of 27 days less in hospital than those with remission induction, ie, the median time in hospital was 15 days (range 7-64) versus 42 days (27-121, U test p<0·0001), respectively. INTERPRETATION: Non-inferiority of disease control could not be shown at the 2·5% significance level. The rate of treatment success was also not statistically better for patients with remission induction. Watchful waiting and immediate transplantation could be an alternative for fit patients with poor response or relapsed acute myeloid leukaemia who have a stem cell donor available. More randomised controlled intention-to-transplant trials are needed to define the optimal treatment before transplantation for patients with active acute myeloid leukaemia. FUNDING: DKMS and the Gert and Susanna Mayer Stiftung Foundation.
引用
- Stelljes M, Middeke JM, Bug G, et al. Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial. Lancet Haematol. 2024. PMID: 38583455. doi:10.1016/S2352-3026(24)00065-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。